"Action by our Senators in
supporting this change is especially welcomed by the patient
community," said Colleen Zak, Executive Director of the Autosomal
Recessive Polycystic Kidney Disease and Congenital Hepatic
Fibrosis (ARPKD/CHF) Alliance. "Delivering on the NIH public
access policy will create anticipated opportunities for
accelerating research and finding cures."
